Shirley Chen
Stock Analyst at Barclays
(2.94)
# 2,620
Out of 4,408 analysts
36
Total ratings
61.5%
Success rate
5.7%
Average return
Main Sectors:
Stocks Rated by Shirley Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €22.00 | $24.82 | -11.36% | 4 | May 7, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 350.00 → kr 470.00 | $436.80 | +7.60% | 5 | Feb 24, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €105.00 | $76.65 | +36.99% | 1 | Dec 15, 2025 | |
| SWX: NOVN Novartis AG | Maintained: Sell | CHF 90.00 | $122.18 | -26.34% | 6 | Nov 21, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,875 → kr 2,000 | $1,619.67 | +23.48% | 9 | Nov 10, 2025 | |
| LON: GSK GSK plc | Maintained: Hold | 1,450p | $1,985.50 | -26.97% | 6 | Oct 31, 2025 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 14,000p | $13,520.00 | +3.55% | 5 | Oct 21, 2025 |
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €22.00
Current: $24.82
Upside: -11.36%
Swedish Orphan Biovitrum AB (publ)
Feb 24, 2026
Maintained: Buy
Price Target: kr 350.00 → kr 470.00
Current: $436.80
Upside: +7.60%
Sanofi
Dec 15, 2025
Maintained: Buy
Price Target: €105.00
Current: $76.65
Upside: +36.99%
Novartis AG
Nov 21, 2025
Maintained: Sell
Price Target: CHF 90.00
Current: $122.18
Upside: -26.34%
Genmab A/S
Nov 10, 2025
Maintained: Buy
Price Target: kr 1,875 → kr 2,000
Current: $1,619.67
Upside: +23.48%
GSK plc
Oct 31, 2025
Maintained: Hold
Price Target: 1,450p
Current: $1,985.50
Upside: -26.97%
AstraZeneca PLC
Oct 21, 2025
Maintained: Buy
Price Target: 14,000p
Current: $13,520.00
Upside: +3.55%